LiveTiles share price falls after Wizdom achieves earn-out

The Livetiles Ltd (ASX: LVT) share price dropped 4.41% lower today after announcing that Wizdom has successfully met its earn-out conditions.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Livetiles Ltd (ASX: LVT) share price dropped 4.41% lower today after the company announced that Wizdom has successfully met its earn-out conditions following strong growth.

LiveTiles acquired Wizdom, Europe's leading intranet business, in February 2019 for an upfront consideration of $9 million cash and $19 million in LiveTiles shares. 

What does LiveTiles do?

LiveTiles supplies tools to create dashboards, employee portals, and corporate intranets that can be enhanced by artificial intelligence and analytics. LiveTiles is headquartered in New York with operations across the US, Europe, and Australia.

As at November, LiveTiles reported $42.9 million in annualised recurring revenue and is targeting $100 million by June 2021. 

The company estimates its addressable market to be worth $13 billion and consist of some 300,000 customers. LiveTiles landed its first paying customer in February 2015 and now boasts more than 900 customers across every major industry vertical.

Wizdom acquisition 

Wizdom is a leading 'plug and play' Microsoft-aligned workplace software business. At the time of the acquisition, Wizdom had a strong European footprint with 243 Software-as-a-Service (SaaS) customers including Nokia and De Beers. 

Wizdom's software is built on the same Microsoft technology platforms as LiveTiles. The acquisition extended LiveTiles' product portfolio with a complementary offering. As such, Wizdom has driven significant growth in LiveTiles' average contract value with strong uptake by large enterprise customers and growing demand for bundled deals combining Wizdom, LiveTiles, and Hyperfish technology. 

Terms of the earn-out 

As at 31 December 2018, Wizdom's annual recurring revenue (ARR) was A$8 million. Under the acquisition, an earn-out of up to $16 million applied if Wizdom could achieve ARR of at least €8 million and positive earnings before interest, tax, depreciation and amortisation (EBITDA) for the 12 months to 31 January 2020. 

Today, LiveTiles revealed that Wizdom has achieved strong ARR growth of 87% in the period to 31 January, with ARR increasing to $15 million. Wizdom also generated positive EBITDA during the period. 

The earn-out consideration is to be paid 25% in cash and 75% in LiveTiles shares, with $4 million in cash to be paid and 40,127,954 LiveTiles shares to be issued at an issue price of 30 cents per share. The cash component will be paid out of LiveTiles' existing cash resources. 

Integration

Wizdom's sales, marketing, finance and product teams are more fully integrated into LiveTiles' organisational structure. All key team members have been retained since the acquisition including the co-founders. 

LiveTiles CEO and co-founder Karl Redenbach said, "it is pleasing to see Wizdom perform so strongly in the first year post acquisition and we are confident Wizdom will continue to be a key driver of our strong enterprise customer and revenue growth in FY20 and beyond."

Motley Fool contributor Kate O'Brien has no position in any of the stocks mentioned. The Motley Fool Australia has recommended LIVETILES FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Man in business suit carries box of personal effects
Share Market News

Regis Healthcare CEO resignation: Leadership transition update

Regis Healthcare has announced the resignation of CEO Dr Linda Mellors after six years, with a leadership search now underway.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Share Market News

Aurizon lodges new 10-year network access undertaking with QCA

Aurizon is lodging a decade-long network access deal that impacts the company’s revenue and operational certainty through to 2037.

Read more »

A man holds his head in his hands after seeing bad news on his laptop screen.
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

Woman relaxing on her phone on her couch, symbolising passive income.
Share Market News

Stockland announces estimated 1H26 distribution

Stockland declares a 9.0c estimated 1H26 distribution and maintains its DRP for the period.

Read more »

Cheerful businesspeople shaking hands in the office.
Share Market News

Champion Iron launches $289m Rana Gruber takeover: what shareholders need to know

Champion Iron has moved to acquire Norway’s Rana Gruber in a $289 million deal backed by new financing and key…

Read more »

Two boys play outside on an old army tank.
Opinions

What's next on the horizon for EOS? Why I think 2026 could be massive

EOS is entering a new growth phase, with a growing backlog, deep pipeline, and multiple large defence contracts on the…

Read more »

A happy man and woman sit having a coffee in a cafe while she holds up her phone to show him the ASX shares that did best today.
Share Market News

NEXTDC lifts contracted utilisation and order book in December update

NEXTDC has ramped up its contracted utilisation and forward order book, flagging ongoing revenue growth over the next several years.

Read more »

Successful group of people applauding in a business meeting and looking very happy.
Share Market News

Telix Pharmaceuticals in focus with China trial success and FDA updates

Telix Pharmaceuticals posts positive China Phase 3 results for Illuccix and advances its FDA applications.

Read more »